Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A2 | P19784 | 15/20 | 0.71 |
| ▸ | CSNK2B | P67870 | 15/20 | 0.71 |
| ▸ | CSNK2A1 | P68400 | 13/20 | 0.67 |
| ▸ | PARP1 | P09874 | 1/20 | 0.56 |
| ▸ | CLK2 | P49760 | 4/20 | 0.49 |
| ▸ | CSNK2A3 | Q8NEV1 | 4/20 | 0.49 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.48 |
| ▸ | GAK | O14976 | 1/20 | 0.48 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.48 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.48 |
| ▸ | ULK1 | O75385 | 1/20 | 0.48 |
| ▸ | STK10 | O94804 | 1/20 | 0.48 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.48 |
| ▸ | CDK1 | P06493 | 1/20 | 0.48 |
| ▸ | PIM1 | P11309 | 1/20 | 0.48 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.48 |
| ▸ | PHKG2 | P15735 | 1/20 | 0.48 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.48 |
| ▸ | CDK2 | P24941 | 1/20 | 0.48 |
| ▸ | TYK2 | P29597 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2690184 | 0.95 | CSNK2A2 (0.68) | CSNK2A2CSNK2BCSNK2A1PARP1CLK2 | |
| SCHEMBL10134627 | 0.90 | CSNK2A2 (0.58) | CSNK2A2CSNK2BCSNK2A1PARP1PIM1 | |
| SCHEMBL8890757 | 0.86 | CSNK2A1 (0.66) | CSNK2A2CSNK2BCSNK2A1PARP1 | |
| SCHEMBL12824331 | 0.83 | CSNK2A2 (1.00) | CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL10131328 | 0.82 | CSNK2A1 (0.72) | CSNK2A2CSNK2BCSNK2A1PARP1PIM1 | |
| SCHEMBL10134624 | 0.82 | CSNK2A2 (0.51) | CSNK2A2CSNK2BCSNK2A1PARP1PIM1 | |
| SCHEMBL1450213 | 0.81 | CSNK2A2 (0.80) | CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL20704185 | 0.81 | HIPK2 (0.68) | CSNK2A2CSNK2BCSNK2A1PARP1 | |
| SCHEMBL629907 | 0.80 | CSNK2A1 (1.00) | CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL2689292 | 0.79 | CSNK2A1 (0.80) | CSNK2A2CSNK2BCSNK2A1CLK2CSNK2A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12383624-B2 | Cargo delivery system and composition comprising the same | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2025-08-12 | — | — | US | disclosed |
| WO-2023126951-A1 | INHIBITORS OF AUTOPHAGY-RELATED PROTEIN-PROTEIN INTERACTIONS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2023-07-06 | — | — | WO | disclosed |
| WO-2023126951-A1 | INHIBITORS OF AUTOPHAGY-RELATED PROTEIN-PROTEIN INTERACTIONS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2023-07-06 | — | — | WO | disclosed |
| US-20230190938-A1 | NOVEL CARGO DELIVERY SYSTEM AND COMPOSITION COMPRISING THE SAME | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2023-06-22 | — | — | US | disclosed |
| US-20230190938-A1 | NOVEL CARGO DELIVERY SYSTEM AND COMPOSITION COMPRISING THE SAME | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2023-06-22 | — | — | US | disclosed |
| US-20230190938-A1 | NOVEL CARGO DELIVERY SYSTEM AND COMPOSITION COMPRISING THE SAME | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2023-06-22 | — | — | US | disclosed |
| US-11071727-B2 | Therapeutic targeting of proteolytic cleavage of the mixed lineage leukemia gene product (MLL1) by taspase1 using kinase inhibitors | NORTHWESTERN UNIVERSITY (US) | 2021-07-27 | — | — | US | disclosed |
| US-20190231759-A1 | THERAPEUTIC TARGETING OF PROTEOLYTIC CLEAVAGE OF THE MIXED LINEAGE LEUKEMIA GENE PRODUCT (MLL1) BY TASPASE1 USING KINASE INHIBITORS | NORTHWESTERN UNIVERSITY (US) | 2019-08-01 | — | — | US | disclosed |
| US-9062043-B2 | Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators | SENHWA BIOSCIENCES, INC. (TW) | 2015-06-23 | — | — | US | disclosed |
| US-9062043-B2 | Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators | SENHWA BIOSCIENCES, INC. (TW) | 2015-06-23 | — | — | US | disclosed |
| WO-2009097014-A2 | THERAPEUTIC KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2009-08-06 | — | — | WO | disclosed |
| EP-2061765-A2 | SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | Cylene Pharmaceuticals, Inc. (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20090105233-A1 | SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | SENHWA BIOSCIENCES, INC. (TW) | 2009-04-23 | — | — | US | disclosed |
| US-20090105233-A1 | SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | SENHWA BIOSCIENCES, INC. (TW) | 2009-04-23 | — | — | US | disclosed |
| US-20090105233-A1 | SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | SENHWA BIOSCIENCES, INC. (TW) | 2009-04-23 | — | — | US | disclosed |
| US-20090093465-A1 | THERAPEUTIC KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2009-04-09 | — | — | US | disclosed |
| US-20090093465-A1 | THERAPEUTIC KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2009-04-09 | — | — | US | disclosed |
| US-20090093465-A1 | THERAPEUTIC KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2009-04-09 | — | — | US | disclosed |
| WO-2008028168-A2 | SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2008-03-06 | — | — | WO | disclosed |
| WO-2008028168-A2 | SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190231759-A1 | THERAPEUTIC TARGETING OF PROTEOLYTIC CLEAVAGE OF THE MIXED LINEAGE LEUKEMIA GENE PRODUCT (MLL1) BY TASPASE1 USING KINASE INHIBITORS | MLLT1, TASP1, MLLT3 | CSNK2A2 40/4885CSNK2B 58/4885CSNK2A1 38/4885 |
| US-20230190938-A1 | NOVEL CARGO DELIVERY SYSTEM AND COMPOSITION COMPRISING THE SAME | ATG7, SQSTM1, BECN1 | CSNK2A2 983/4885CSNK2B 952/4885CSNK2A1 956/4885 |
| US-12383624-B2 | Cargo delivery system and composition comprising the same | ATG7, SQSTM1, BECN1 | CSNK2A2 1148/4885CSNK2B 1185/4885CSNK2A1 1104/4885 |
| US-20090093465-A1 | THERAPEUTIC KINASE MODULATORS | PACSIN2, CKS1B, CSNK1A1 | CSNK2A2 11/4885CSNK2B 16/4885CSNK2A1 6/4885 |
| US-20090105233-A1 | SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | PACSIN2, TNKS, PARP1 | CSNK2A2 37/4885CSNK2B 39/4885CSNK2A1 24/4885 |
| US-11071727-B2 | Therapeutic targeting of proteolytic cleavage of the mixed lineage leukemia gene product (MLL1) by taspase1 using kinase inhibitors | MLLT1, TASP1, MLLT3 | CSNK2A2 40/4885CSNK2B 58/4885CSNK2A1 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.